Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DAJ3D2
|
|||
| Drug Name |
SMI-4a
|
|||
| Synonyms |
438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C11H6F3NO2S
|
|||
| Canonical SMILES |
C1=CC(=CC(=C1)C(F)(F)F)C=C2C(=O)NC(=O)S2
|
|||
| InChI |
1S/C11H6F3NO2S/c12-11(13,14)7-3-1-2-6(4-7)5-8-9(16)15-10(17)18-8/h1-5H,(H,15,16,17)/b8-5-
|
|||
| InChIKey |
NGJLOFCOEOHFKQ-YVMONPNESA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Serine/threonine-protein kinase pim-1 (PIM1) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Jak-STAT signaling pathway | |||
| MicroRNAs in cancer | ||||
| Acute myeloid leukemia | ||||
| NetPath Pathway | IL9 Signaling Pathway | |||
| IL5 Signaling Pathway | ||||
| IL2 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | ||||
| TCR Signaling Pathway | ||||
| Pathway Interaction Database | GMCSF-mediated signaling events | |||
| Validated targets of C-MYC transcriptional activation | ||||
| Role of Calcineurin-dependent NFAT signaling in lymphocytes | ||||
| IL5-mediated signaling events | ||||
| IL3-mediated signaling events | ||||
| C-MYB transcription factor network | ||||
| WikiPathways | Ectoderm Differentiation | |||
| Hematopoietic Stem Cell Differentiation | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Pim-1 inhibitor SMI-4a suppresses tumor growth in non-small cell lung cancer via PI3K/AKT/mTOR pathway. Onco Targets Ther. 2019 Apr 23;12:3043-3050. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.